Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Lapsina, Sandra; Nagler, Nicole; Müller, Simon F.; Holtdirk, Annette; Kottmann, Tanja; Müller, Elisabeth; von Luckner, Jennifer; Schäfer, Ingo

doi:10.3390/ani13111853

Cited by 3 publications

(10 citation statements)

References 41 publications

(78 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

Section: Discussionmentioning

confidence: 99%

“…The FGF-23 ELISA Kit (Kainos Laboratories, Tokyo, Japan) demonstrated the best diagnostic performance in a study by the same authors in 2023 when three different FGF-23 assays were compared in cats [ 23 ]. Although originally developed to detect human FGF-23, this assay was soon successfully applied in cats as well [ 15 , 17 , 23 ]. The knowledge regarding RIs for this FGF-23 ELISA kit is currently based on two studies demonstrating RIs of 56 to 700 pg/mL in 79 cats [ 15 ] and 0 to 366 pg/mL in 108 cats [ 20 ].…”

Section: Discussionmentioning

confidence: 99%

“…According to the manufacturer’s specifications, the minimum detection limit for the Kainos ELISA assay was 3 pg/mL, while the quantification range spanned 3–800 pg/mL. In the LABOKLIN laboratory, coefficients of variation of <15% are considered to indicate a good performance of the chosen diagnostic assay in cats [ 23 ]. In detail, the intra-assay precision in the LABOKLIN laboratory showed coefficients of variation of 12.54%, 4.17%, and 4.19%, while inter-assay precision values were 9.2%, 9.96%, and 8.17% for samples with low, moderate, and high FGF-23 levels, respectively [ 23 ].…”

Section: Methodsmentioning

confidence: 99%

“…The following diagnostic quantitative enzyme-linked immunosorbent assay (ELISA) kits have been tested: the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) by four studies [ 15 , 17 , 19 , 20 ], the MyBioSource ELISA (MyBioSource, San Diego, CA, USA) by two studies [ 16 , 21 ], and the MedFrontier FGF23 ELISA (Minaris Medical Co., Tokyo, Japan) by another study [ 22 ]. In a study from 2023 performed by the same authors, where the FGF-23 ELISA kit, the MyBioSource ELISA, and the LIAISON FGF 23 kit for intact FGF-23 were all compared on the Liaison platform developed by DiaSorin (Saluggia, Italy), the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) demonstrated the best correlation with various creatinine concentrations according to the IRIS [ 23 ]. The intra- and interassay coefficients of variation (CVs) of this assay were all below 15%, thus indicating a reliable performance [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

“…In a study from 2023 performed by the same authors, where the FGF-23 ELISA kit, the MyBioSource ELISA, and the LIAISON FGF 23 kit for intact FGF-23 were all compared on the Liaison platform developed by DiaSorin (Saluggia, Italy), the FGF-23 ELISA kit (Kainos Laboratories, Tokyo, Japan) demonstrated the best correlation with various creatinine concentrations according to the IRIS [ 23 ]. The intra- and interassay coefficients of variation (CVs) of this assay were all below 15%, thus indicating a reliable performance [ 23 ].…”

Section: Introductionmentioning

confidence: 99%

See 4 more Smart Citations

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Lapsina,

von Luckner,

Nagler

et al. 2024

Animals

Self Cite

View full text Add to dashboard Cite

Fibroblast growth factor (FGF)-23 is a phosphaturic hormone. An association between increasing FGF-23 levels and progression of chronic kidney disease (CKD) was documented in cats, dogs, and humans. The information regarding reference intervals (RIs) of FGF-23 in cats is limited. We aimed to establish RIs in a large cohort of clinically healthy cats and to investigate correlations with sex and age. A total of 118 cats with unremarkable complete blood count and serum chemistry profile were included. Clinically sick cats, cats with concurrent diseases, suspicion of CKD, or receiving renal diets were excluded. FGF-23 concentrations were measured with the FGF-23 ELISA Kit. RIs were calculated using the reference interval advisor software 2.1 (Microsoft Excel). FGF-23 concentrations were correlated with sex and age. The RI for FGF-23 concentrations spanned 85.8 to 387.0 pg/mL (90% confidence interval: lower limit 40.5 to 103.9 pg/mL, upper limit: 354.6 to 425.0 pg/mL). No significant relationships (r2 = 0.044) were detected with age (p = 0.081) or sex (p = 0.191). Other studies of the same diagnostic assay calculated RIs of 56 to 700 pg/mL in 79 cats and <336 pg/mL in 108 cats, and in concordance with the present study, did not detect any correlation with sex or age.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Lapsina,

von Luckner,

Nagler

et al. 2024

Animals

Self Cite

View full text Add to dashboard Cite

show abstract

Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Summers,

Michael,

Szlosek

et al. 2024

Journal of Feline Medicine and Surgery

View full text Add to dashboard Cite

Objectives This study undertook a scoping review of research on blood fibroblast growth factor 23 (FGF-23) concentrations in healthy non-azotemic cats and cats with chronic kidney disease (CKD) to describe the volume and nature of existing literature, to determine whether published studies provide adequate evidence to support the use of FGF-23 as a biomarker in clinical practice and to identify any existing gaps in knowledge. Methods PRISMA Extension for Scoping Reviews guidelines were used to design and perform the scoping review. Online databases were used to identify observational and clinical studies of blood FGF-23 concentrations in healthy cats and cats with CKD published before December 2022. Study and population characteristics and descriptive data on FGF-23 concentrations were extracted. Results A total of 205 publications were reviewed; 17 were retained for inclusion. Most studies were retrospective. Most studies included cats with International Renal Interest Society stage 2–4 CKD, with some variation. Key concepts explored in the literature include FGF-23 concentrations by CKD stage, effect of dietary phosphate restriction on FGF-23 concentrations, relationship between FGF-23 concentrations and blood phosphorus, calcium and magnesium concentrations, and FGF-23 concentrations in cats with progressive CKD. FGF-23 concentrations tended to be higher in cats with CKD compared with healthy cats, with an overlap between healthy and CKD populations, and there was significant variation within stages of CKD. Conclusions and relevance FGF-23 is a biomarker of interest for the management and monitoring of phosphate overload in cats. Studies support several potential clinical applications for measuring FGF-23 concentration in practice; however, evidence is limited. Research on FGF-23 in cats with CKD would benefit from longitudinal, prospective studies that standardize CKD diagnosis and categorize cats by stage using current guidelines. Studies should include cats with early-stage, non-azotemic CKD and use commercially available assays so such results are comparable across studies.

show abstract

Fibroblast Growth Factor-23 (FGF-23) in Dogs—Reference Interval and Correlation with Hematological and Biochemical Parameters

Lapsina,

Nagler,

Müller

et al. 2023

Animals

Self Cite

View full text Add to dashboard Cite

Fibroblast growth factor-23 (FGF-23) is a phosphaturic hormone used to monitor chronic kidney disease (CKD) in humans. The aims of this study were (1) to determine the intra- and interassay precision of the FGF-23 concentrations in dogs as measured via the Kainos ELISA FGF-23 kit, (2) to calculate a reference interval, and (3) to assess the correlation of the FGF-23 concentration with the hematological and biochemical parameters. The coefficient of variation was below 15% for both the intra- and interassay precision, indicating good reproducibility. The reference interval ranged between 95.8 (90% confidence interval: 44.6; 139.2) and 695.1 pg/mL (598.7; 799.1) based on 136 clinically healthy dogs, classified as such according to the information of treating veterinarians as well as the unremarkable results of hematology and biochemistry. The FGF-23 concentration differed significantly between dogs aged <9 and ≥9 years (p = 0.045). Four groups of 10 dogs each were retrospectively formed based on the creatinine concentration classification according to the IRIS staging. Correlation was the strongest for the renal parameters. Statistically significant differences in the FGF-23 concentration were demonstrated between the study groups I and III (p < 0.001), I and IV (p < 0.001), and II and IV (p = 0.005). There was a trend for a rising FGF-23 concentration in older dogs. Due to the wide reference interval, diagnostic cut-offs and/or subject-based FGF-23 reference values in each dog are needed for monitoring and clinical interpretation.

show abstract

Comparison of Three Different Diagnostic Assays for Fibroblast Growth Factor-23 (FGF-23) Measurements in Cats: A Pilot Study

Cited by 3 publications

References 41 publications

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Establishing a Reference Interval for Fibroblast Growth Factor (FGF)-23 in Cats

Blood fibroblast growth factor 23 concentration in cats with and without chronic kidney disease: a scoping review

Fibroblast Growth Factor-23 (FGF-23) in Dogs—Reference Interval and Correlation with Hematological and Biochemical Parameters

Contact Info

Product

Resources

About